There are no bad anticancer agents, only bad clinical trial designs-twenty-first Richard and Hinda Rosenthal foundation award lecture, Clinical Cancer Research, vol.4, issue.5, pp.1079-1086, 1998. ,
Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint, Controlled Clinical Trials, vol.21, issue.4, pp.343-359, 2000. ,
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers, Journal of Clinical Oncology, vol.28, issue.33, pp.4877-4883, 2010. ,
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial, Cancer Discovery, vol.7, issue.6, pp.586-595, 2017. ,
Precision oncology: The UC San Diego moores cancer center predict experience, Molecular Cancer Therapeutics, vol.15, issue.4, pp.743-752, 2016. ,
Use of the ratio of time to progression following first-and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma, Annals of Oncology, vol.12, issue.2, pp.187-191, 2001. ,
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Cross-over analysis from the SHIVA trial, Annals of Oncology, vol.28, pp.592-596, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01791290
Sequential versus combination chemotherapy for the treatment of advanced 8 Computational and Mathematical Methods in Medicine colorectal cancer (FFCD 2000-05): An open-label, randomised, phase 3 trial, The Lancet Oncology, vol.12, issue.11, pp.1032-1044, 2011. ,
Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial, European Journal of Cancer, vol.49, issue.8, pp.1882-1888, 2013. ,
The frailty model, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-01602399
parfm: parametric frailty models in R, Journal of Statistical Software, vol.51, issue.11, 2012. ,
Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint, Contemporary Clinical Trials, vol.32, issue.1, pp.99-107, 2011. ,
Impact of chemotherapy beyond the first line in patients with metastatic breast cancer, Breast Cancer Research and Treatment, vol.107, issue.2, pp.275-279, 2008. ,
Midrank unification of rank tests for exact, tied, and censored data, Journal of Nonparametric Statistics, vol.14, issue.5, pp.569-581, 2002. ,
A power analysis of tests for paired lifetime data, Lifetime Data Analysis, vol.11, issue.2, pp.233-243, 2005. ,
Guideline on the evaluation of anticancer medicinal products in man, European Medicines Agency, vol.44, p.33, 2012. ,
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy, Annals of Oncology, vol.24, issue.2, pp.537-542, 2013. ,
Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials, Journal of Clinical Oncology, vol.27, issue.35, pp.5958-5964, 2009. ,
When you look matters: The effect of assessment schedule on progression-free survival, Journal of the National Cancer Institute, vol.99, issue.6, pp.428-432, 2007. ,